FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141473743> ?p ?o ?g. }

• W3141473743 endingPage "e214132" @default.
• W3141473743 startingPage "e214132" @default.
• W3141473743 abstract "<h3>Importance</h3> The US Food and Drug Administration (FDA) highlighted the potential risk of hepatitis B reactivation that was associated with Bcr-Abl tyrosine kinase inhibitor (TKI) treatment and has required updated product labels. <h3>Objective</h3> To examine the association between hepatitis B flare and exposure to Bcr-Abl TKIs compared with non–Bcr-Abl TKIs. <h3>Design, Setting, and Participants</h3> This nested case-control study included patients who entered a hepatitis B carrier cohort in Taiwan after January 1, 2005. Patients who received their first antiviral agents for hepatitis B flare for more than 28 days after the cohort entry date were included as case patients. For each case, a corresponding risk set was formed that included all eligible patients in the study cohort who had the same age (within 1 year), same sex, and were at risk of developing hepatitis B flare at the case date. As many as 10 control patients were randomly selected from the risk set for each case patient. TKIs were evaluated before the hepatitis B flare for case patients and before the corresponding index date for control patients. Data were collected from the Taiwan National Health Insurance research database from January 2000 to 2015. Data analysis was conducted from January to June 2019. <h3>Exposure</h3> Use of Bcr-AbL TKIs. <h3>Main Outcomes and Measures</h3> Conditional logistic regression was used to estimate the rate ratio for the association between hepatitis B flare and exposure to Bcr-Abl TKIs compared with non–Bcr-Abl TKIs. <h3>Results</h3> Among 698 342 patients who carried incident hepatitis B virus, 66 702 patients with hepatitis B flare that required antiviral treatment (47 492 [71.2%] men; mean [SD] age at index date, 50.2 [13.8] years) were included as case patients, and 666 989 age and sex–matched patients (474 903 [71.2%] men; mean [SD] age, 50.2 [13.8] years) were included as control patients. Analysis revealed that Bcr-Abl TKI use during the previous 90 days was independently associated with a 56% higher risk of hepatitis B flare (adjusted rate ratio [aRR], 1.56; 95% CI, 1.11-2.20), and the aRR increased to 1.66 (95% CI, 1.20-2.28) for Bcr-Abl TKI use during the previous 365 days. Use of Bcr-AbL TKIs during the previous 60 days was associated with a significantly increased risk of flare among women (aRR, 3.20; 95% CI, 1.70-6.03) but not among men (aRR, 1.14; 95% CI, 0.72-1.81). <h3>Conclusions and Relevance</h3> These findings suggest that sex-specific strategies may be needed to monitor for hepatitis B reactivation among patients receiving Bcr-Abl TKIs." @default.
• W3141473743 created "2021-04-13" @default.
• W3141473743 creator A5029478162 @default.
• W3141473743 creator A5032042455 @default.
• W3141473743 creator A5045255444 @default.
• W3141473743 creator A5049093012 @default.
• W3141473743 creator A5067648360 @default.
• W3141473743 date "2021-04-06" @default.
• W3141473743 modified "2023-10-17" @default.
• W3141473743 title "Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan" @default.
• W3141473743 cites W1497552522 @default.
• W3141473743 cites W1967749640 @default.
• W3141473743 cites W1991464577 @default.
• W3141473743 cites W1994351795 @default.
• W3141473743 cites W2007113606 @default.
• W3141473743 cites W2010993971 @default.
• W3141473743 cites W2014582878 @default.
• W3141473743 cites W2028822747 @default.
• W3141473743 cites W2065902287 @default.
• W3141473743 cites W2077080958 @default.
• W3141473743 cites W2081336417 @default.
• W3141473743 cites W2083971244 @default.
• W3141473743 cites W2087595943 @default.
• W3141473743 cites W2106595552 @default.
• W3141473743 cites W2117819389 @default.
• W3141473743 cites W2136202467 @default.
• W3141473743 cites W2142373239 @default.
• W3141473743 cites W2499715519 @default.
• W3141473743 cites W2547391316 @default.
• W3141473743 cites W2553957395 @default.
• W3141473743 cites W2590941489 @default.
• W3141473743 cites W2612175225 @default.
• W3141473743 cites W2782941694 @default.
• W3141473743 cites W2792735085 @default.
• W3141473743 cites W2895221593 @default.
• W3141473743 cites W2896847025 @default.
• W3141473743 cites W2911749115 @default.
• W3141473743 cites W2960526624 @default.
• W3141473743 cites W2979527477 @default.
• W3141473743 cites W3031602500 @default.
• W3141473743 cites W4243522787 @default.
• W3141473743 doi "https://doi.org/10.1001/jamanetworkopen.2021.4132" @default.
• W3141473743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8025118" @default.
• W3141473743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33822067" @default.
• W3141473743 hasPublicationYear "2021" @default.
• W3141473743 type Work @default.
• W3141473743 sameAs 3141473743 @default.
• W3141473743 citedByCount "4" @default.
• W3141473743 countsByYear W31414737432022 @default.
• W3141473743 countsByYear W31414737432023 @default.
• W3141473743 crossrefType "journal-article" @default.
• W3141473743 hasAuthorship W3141473743A5029478162 @default.
• W3141473743 hasAuthorship W3141473743A5032042455 @default.
• W3141473743 hasAuthorship W3141473743A5045255444 @default.
• W3141473743 hasAuthorship W3141473743A5049093012 @default.
• W3141473743 hasAuthorship W3141473743A5067648360 @default.
• W3141473743 hasBestOaLocation W31414737431 @default.
• W3141473743 hasConcept C126322002 @default.
• W3141473743 hasConcept C159047783 @default.
• W3141473743 hasConcept C203014093 @default.
• W3141473743 hasConcept C2777382497 @default.
• W3141473743 hasConcept C71924100 @default.
• W3141473743 hasConcept C72563966 @default.
• W3141473743 hasConceptScore W3141473743C126322002 @default.
• W3141473743 hasConceptScore W3141473743C159047783 @default.
• W3141473743 hasConceptScore W3141473743C203014093 @default.
• W3141473743 hasConceptScore W3141473743C2777382497 @default.
• W3141473743 hasConceptScore W3141473743C71924100 @default.
• W3141473743 hasConceptScore W3141473743C72563966 @default.
• W3141473743 hasIssue "4" @default.
• W3141473743 hasLocation W31414737431 @default.
• W3141473743 hasLocation W31414737432 @default.
• W3141473743 hasOpenAccess W3141473743 @default.
• W3141473743 hasPrimaryLocation W31414737431 @default.
• W3141473743 hasRelatedWork W2007764585 @default.
• W3141473743 hasRelatedWork W2070338448 @default.
• W3141473743 hasRelatedWork W2315085516 @default.
• W3141473743 hasRelatedWork W2316407790 @default.
• W3141473743 hasRelatedWork W2330239290 @default.
• W3141473743 hasRelatedWork W2416115367 @default.
• W3141473743 hasRelatedWork W2603773853 @default.
• W3141473743 hasRelatedWork W2952239533 @default.
• W3141473743 hasRelatedWork W2964295425 @default.
• W3141473743 hasRelatedWork W2999832097 @default.
• W3141473743 hasVolume "4" @default.
• W3141473743 isParatext "false" @default.
• W3141473743 isRetracted "false" @default.
• W3141473743 magId "3141473743" @default.
• W3141473743 workType "article" @default.